Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-11-28
2006-11-28
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100
Reexamination Certificate
active
07141243
ABSTRACT:
The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.
REFERENCES:
patent: 5674735 (1997-10-01), Onions et al.
patent: 5853715 (1998-12-01), Macek et al.
patent: 6083511 (2000-07-01), Onions et al.
patent: 6187320 (2001-02-01), Darai et al.
patent: 6193983 (2001-02-01), Crabb et al.
patent: 6387685 (2002-05-01), Markham et al.
patent: 6703231 (2004-03-01), Elbers et al.
patent: 1129722 (2001-09-01), None
patent: WO 98/26049 (1998-06-01), None
patent: WO 00/08165 (2000-02-01), None
patent: WO 01/17553 (2001-03-01), None
patent: WO 02/09750 (2002-02-01), None
Elizabeth A.R. Telford et al; The DNA Sequence of Equine Herpesvirus—1; Virology (1992) vol. 189 pp. 304-316; Institute of Virology University of Glasglow, Church Street, Glasglow G11 5JR United Kingdom.
Elizabeth A.R. Telford; The DNA sequence of equine herpesvirus—4; Journal of General Virology (1998) vol. 79 pp. 1197-1203; Institute of Virology University of Glasglow Church Street, Glasglow G11 5JR UK.
D.R. Fitzpatrick et al; Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus); Am J. Vet Res. (1984) vol. 45 No. 10 pp. 1947-1952; School of Veterinary Science, University of Melbourne Parkville, Victoria 3052.
Jacobus G.M. Heldens et al; Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV 1,4). Vaccination/challenge experiments in foals and pregnant mares; Vaccine (2001) vol. 19 pp. 4307-4317; Ford Dodge Animal Health Dept. of Bio R&D.
Nikolaus Osterrieder et al; The Equine Herpesvirus 1 Glycoprotein gp21/22a, the Herpes Simplex Virus Type 1 gM Homolog, Is Involved in Virus Penetration and Cell-to-Cell Spread of Virions; Journal of Virology Jun. 1996 vol. 70 No. 6 p. 4110-4115; American Cancer Society for Microbiology.
Antonie Neubauer et al; Equine Herpesvirus 1 Mutants Devoid of Glycoprotein B or M Are Apathogenic for Mice but Induce Protection against Challenge Infection; Virology 1997 vol. 239 pp. 36-45; Institute for Medical Microbiology, Munich, Germany.
Christian Seyboldt et al; Equine Herpesvirus 1 (EHV-1) Glycoprotein M: Effect of Deletions of Transmembrane Domains; Virology 2000 vol. 278 pp. 477-489; Institute of Molecular Biology and Infectology, Insel Reims, Germany.
International Search Report Reference No. PCT/EP 03/07730.
Neubauer Antonie
Ziegler Christina
Boehringer Ingelheim Vetmedica GmbH
Devlin Mary-Ellen M.
Morris Michael P.
Salimi Ali R.
LandOfFree
gM-negative EHV-mutants without heterologous elements does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with gM-negative EHV-mutants without heterologous elements, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and gM-negative EHV-mutants without heterologous elements will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3660087